

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): **June 30, 2014**

CNS RESPONSE, INC.

(Exact name of Company as specified in its charter)

Delaware
(State or other
jurisdiction of
incorporation)

001-35527

(Commission File No.)

87-0419387
(I.R.S. Employer
Identification No.)

85 Enterprise, Suite 410
Aliso Viejo, CA 92656
(Address of principal executive offices)

(949) 420-4400

(Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 7.01 Regulation FD Disclosure.

On June 30, 2014, CNS Response, Inc. (the “Company”) was informed that its scientific paper titled “The Use of Psychiatric Electroencephalography Evaluation Registry (PEER) to Personalize Pharmacotherapy” has been accepted for publication by the peer-reviewed journal of *Neuropsychiatric Disease and Treatment*.

The Company is conducting a joint clinical study of its patented PEER technology led by Walter Reed National Military Medical Center. In the Quarterly Report for the period ending March 31, 2014, filed with the Securities and Exchange Commission on May 15, 2014, it was disclosed that the publication of interim data, in accordance with the study protocol, was anticipated during the first half of calendar 2014, or shortly thereafter, subject to among other things, military sign-offs, peer reviews of the scientific paper and the publication schedule of the journal. The analysis of interim study data has shown statistically significant results, which are consistent with prior published clinical studies. These studies have shown that the use of PEER improved outcomes for treatment resistant depression patients by two to three times¹ when compared with treatment as usual; furthermore, the use of PEER substantially reduced suicidal ideation².

(1) DeBattista C, Kinrys G, Hoffman D, et al. The use of referenced-EEG (rEEG) in assisting medication selection for the treatment of depression. *Journal of Psychiatric Research*. 2011;45(1):64-75.

(2) Hoffman DA, DeBattista C, Valuck RJ, Iosifescu DV. Measuring severe adverse events and medication selection using “PEER Report” for non-psychotic patients: a retrospective chart review. *Neuropsychiatric Disease and Treatment*. 2012;8:277-284.

SIGNATURES

Pursuant to the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CNS Response, Inc.

July 3, 2014

By: /s/ Paul Buck
Paul Buck
Chief Financial Officer
